



PRESS RELEASE MARCH 15<sup>th</sup>, 2011

## **MOBERG DERMA SIGNS DISTRIBUTION AGREEMENTS IN SPAIN AND UK**

**Moberg Derma AB (publ) has entered into distribution agreements with AG Farma S.A. in Spain and HairXpertise Ltd in UK for Emtrix<sup>®</sup> – for treatment of discolored and deformed nails resulting from fungal infection (onychomycosis) or psoriasis. Under the agreements, the distributors are granted exclusive rights to market and sell Emtrix<sup>®</sup>.**

"The agreements follow on a positive response in the Nordic market. Already after the first quarter after launch, the product is the market leader in Scandinavia and sold by the major pharmacy chains", comments Moberg Derma's CEO, Peter Wolpert.

### **About Emtrix<sup>®</sup> and nail diseases**

Emtrix<sup>®</sup> is a prescription free, topical nail product and has the potential to become first-line treatment for common nail disorders. Launch of Emtrix<sup>®</sup> was initiated in the first markets in September 2010. Safety and efficacy has been demonstrated in several clinical studies including more than 500 patients. Emtrix<sup>®</sup> has a unique and rapid mechanism of action which brings visible improvements within 2-4 weeks of treatment.

Nail fungus is the most common nail disease and afflicts approximately 10% of the general population and is more common in the elderly. The estimated global market potential exceeds USD 1 billion. The untapped potential is significant since many patients remain untreated. It is generally recognized that there is a need for new efficacious and safe topical treatments.

### **For further information, please contact:**

Peter Wolpert, President and CEO of Moberg Derma  
Telephone: +46 8 522 307 00  
Mobile: +46 735 71 35  
E-mail: [peter.wolpert@mobergderma.se](mailto:peter.wolpert@mobergderma.se)

### **About Moberg Derma**

Moberg Derma AB (publ), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company's products are based on proven compounds, which reduce time to market, development costs and risk. The portfolio covers projects in the preclinical phase to approved and launched products. The company began operations at the Karolinska Institute in Stockholm in 2006. Moberg Derma is owned by institutional and private investors, Board and management. For further information, please visit: [www.mobergderma.se](http://www.mobergderma.se)